---
title: "吉利德半年一次的HIV预防注射在晚期试验中证明100%有效"
description: "吉利德半年一次的HIV预防注射在晚期试验中证明100%有效"

---


:::info

“智闻AI“ 是由人工智能编撰的刊物集合，确保您只获得最有价值的信息，旨在助您消除信息差，突破信息茧房的局限。  [了解更多 >>](/)

:::

# 吉利德半年一次的HIV预防注射在晚期试验中证明100%有效

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">


吉利德公司研发的半年一次的HIV预防注射剂lenacapavir在后期临床试验中表现出100%的有效性。接受注射的2000名女性无一感染HIV。试验的成功促使建议向所有参与者提供此治疗。这与目前美国不到一半高风险人群使用的每日药片标准形成对比。像这种长效注射剂的疗法能显著提升全球HIV预防工作的效果。
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 5    | Content provides factual information about a medical trial without evident bias.    |
	| Social Impact | 4     | The news could influence public opinion on HIV prevention methods.    |
	| Credibility    | 5    | Information is based on a late-stage clinical trial, indicating high credibility.    |
	| Potential    | 5    | The successful trial could lead to significant changes in HIV prevention globally.    |
	| Practicality    | 5    | The twice-yearly shot offers a practical alternative to daily pills for HIV prevention.    |
	| Entertainment Value    | 3    | While informative, the content lacks typical entertainment elements.    |
</TabItem>
</Tabs>

[Full article>>](https://science.slashdot.org/story/24/06/22/054242/gileads-twice-yearly-shot-to-prevent-hiv-succeeds-in-late-stage-trial?utm_source=rss1.0mainlinkanon&utm_medium=feed)
